S-1360 Shionogi-GlaxoSmithKline.

Abstract

Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV integrase inhibitor as a potential treatment for HIV infection. As of October 2002, phase II trials were ongoing and launch is expected in 2004/2005.

• Authors: Andreas Billich
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 2 Pg. 206-9 (Feb 2003) ISSN: 1472-4472 [Print] England
• PMID: 12669383 (Publication Type: Journal Article, Review)

Chemical References

• Anti-HIV Agents
• Furans
• HIV Integrase Inhibitors
• S 1360
• Triazoles

Topics

• Anti-HIV Agents (adverse effects, metabolism, pharmacology, therapeutic use, toxicity)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Furans
• HIV Infections (drug therapy, virology)
• HIV Integrase Inhibitors (adverse effects, metabolism, pharmacology, therapeutic use, toxicity)
• Humans
• Triazoles